Vascular functions of the plasminogen activation system

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 6, 2007, Pages 1231-1237

  Fay, William P ^a   Garg, Nadish ^b   Sunkar, Madhavi ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b NONE

Author keywords

Atherosclerosis; Fibrinolysis; Mouse; Plasminogen; Vascular remodeling

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRIN; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TRANSFORMING GROWTH FACTOR BETA1; VITRONECTIN;

AORTA; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; BLOOD CLOT LYSIS; BLOOD VESSEL INJURY; CAROTID ARTERY LIGATION; CELL MIGRATION; CELL PROLIFERATION; DNA MODIFICATION; EXTRACELLULAR MATRIX; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFERIOR CAVA VEIN; INTIMA; LUNG EMBOLISM; MOLECULAR GENETICS; MOUSE STRAIN; NONHUMAN; NULL ALLELE; PATHOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SHORT SURVEY; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBRINOLYSIS; HUMANS; HYPERPLASIA; MICE; MICE, KNOCKOUT; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RESEARCH DESIGN; SPECIES SPECIFICITY; THROMBOSIS;

EID: 34249305192     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.140046     Document Type: Short Survey

References (86)

1. Myohanen H, Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cellular Molec Life Sci. 2004;61:2840-2858.
2. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Brit J Haem. 2005;129:307-321.
3. Plow EF, Ploplis VA, Carmeliet P, Collen D. Plasminogen and cell migration in vivo. Fibrinolysis Proteolysis. 1999;13:49-53.
4. Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci. 2005;10:1754-1762.
5. Zhang L, Seiffert D, Fowler BJ, Jenkins GR, Thinnes TC, Loskutoff DJ, Parmer RJ, Miles LA. Plasminogen has a broad extrahepatic distribution. Thromb Haemost. 2002;87:493-501.
6. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost. 2003;89:610-621.
7. Fay WP. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends Cardiovasc Med. 2004;14:196-202.
8. Khil J, Im M, Heath A, Ringdahl U, Mundada L, Cary Engleberg N, Fay WP. Plasminogen enhances virulence of group A streptococci by streptokinase- dependent and streptokinase-independent mechanisms. J Infect Dis. 2003;188:497-505.
9. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, Rozek LS, Wang X, Sjobring U, Ginsburg D. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science. 2004;305:1283-1286.
10. Lahteenmaki K, Edelman S, Korhonen TK. Bacterial metastasis: the host plasminogen system in bacterial invasion. Trends Microbiol. 2005;13:79-85.
11. Collen D, Van Hoef B, Schlott B, Hartmann M, Guhrs KH, Lijnen HR. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. Eur J Biochem. 1993;216:307-314.
12. Wang X, Lin X, Loy J, Tang J, Zhang X. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science. 1998;281:1662-1665.
13. Wang W, Boffa M, Bajzar L, Walker J, Nesheim M. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176-27181.
14. Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997;78:386-391.
15. Broze GJ Jr, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: Role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815-3823.
16. Parker AC, Mundada LV, Schmaier AH, Fay WP. Factor VLeiden inhibits fibrinolysis in vivo. Circulation. 2004;110:3594-3598.
17. Lijnen HR, Van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem. 1994;224:863-871.
18. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation. 1999;99:3050-3055.
19. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 1984;74:1465-1472.
20. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70:327-333.
21. Kawasaki T, Dewerchin M, Lijnen H, Vermylen J, Hoylaerts M. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood. 2000;96:153-160.
22. Schafer K, Muller K, Hecke A, Mounier E, Goebel J, Loskutoff DJ, Konstantinides S. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2003;23:2097-2103.
23. Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost. 1981;46:561-565.
24. Suh TT, Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI, Potter S, Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9:2020-2233.
25. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 1995;9:794-807.
26. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995;92:2585-2593.
27. Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Collen D, Uematsu T. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost. 1999;81:601-604.
28. Schafer K, Konstantinides S, Riedel C, Thinnes T, Muller K, Dellas C, Hasenfuss G, Loskutoff DJ. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation. 2002;106:1847-1852.
29. Farrehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 1998;97:1002-1008.
30. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001;103:576-583.
31. Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, Washington K, Vaughan DE. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood. 2006;107:132-134.
32. Lijnen HR, Okada K, Matsuo O, Collen D, Dewerchin M. Alpha-2-Antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood. 1999;93:2274-2281.
33. Lijnen HR. Gene targeting in hemostasis. Alpha2-antiplasmin. Front Biosci. 2001;6:D239-D247.
34. Dewerchin M, Collen D, Lijnen HR. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha-2-antiplasmin and PAI-1. Thromb Haemost. 2001;86:640-646.
35. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest. 2002;109:101-110.
36. Swaisgood CM, Schmitt D, Eaton, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest. 2002;110:1275-1282.
37. Mao SS, Holahan MA, Bailey C, Wu G, Colussi D, Carroll SS, Cook JJ. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coag Fibrinolysis. 2005;16:407-415.
38. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost. 2006;4:403-410.
39. Drew AF, Tucker HL, Kombrinck KW, Simon DI, Bugge T, Degen JL. Plasminogen is a critical determinant of vascular remodeling in mice. Circ Res. 2000;87:133-139.
40. Carmeliet P, Van Vlaenderen I, Ploplis V, Moons L, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997;99:200-208.
41. Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res. 1997;81:829-839.
42. Quax PH, Lamfers ML, Lardenoye JH, Grimbergen JM, de Vries MR, Slomp J, de Ruiter MC, Kockx MM, Verheijen JH, van Hinsbergh VW. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation. 2001;103:562-569.
43. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol. 2002;22:934-939.
44. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA, Castellino FJ. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol. 2001;158:107-117.
45. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation - A gene targeting and gene transfer study in mice. Circulation. 1997;96:3180-3191.
46. Otsuka G, Agah R, Frutkin AD, Wight TN, Dichek DA. Transforming growth factor beta-1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol. 2006;26:737-743.
47. de Waard V, Arkenbout EK, Carmeliet P, Lindner V, Pannekoek H. Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation mode. Arterioscler Thromb Vasc Biol. 2002;22:1978-1983.
48. Lijnen HR, Van Hoef B, Umans K, Collen D. Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost. 2004;2:16-22.
49. Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation. 2001;103:3105-3110.
50. Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H. Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood. 2004;103:1728-1734.
51. Kawasaki T, Dewerchin M, Lijnen HR, Vreys I, Vermylen J, Hoylaerts MF. Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development. Circ Res. 2001;88:159-166.
52. Lijnen HR, Van Hoef B, Dewerchin M, Collen D. Alpha-2-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury. Arterioscler Thromb Vasc Biol. 2000;20:1488-1492.
53. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer. 2000;82:1702-1708.
54. Chen Y, Budd RC, Kelm RJ Jr, Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol. 2006;26:1777-1783.
55. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha-V beta-3 binding to vitronectin. Nature. 1996;383:441-443.
56. Czekay R-P, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 2003;160:781-791.
57. Deng C, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol. 1996;134:1563-1571.
58. Deng G, Curriden SA, Hu G, Czekay R-P, Loskutoff DJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol. 2001;189:23-33.
59. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004;24:399-404.
60. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Bugge TH, Degen JL. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A. 1997;94:10335-10340.
61. Yee KO, Schwartz SM. Why atherosclerotic vessels narrow: the fibrin hypothesis. Thromb Haemost. 1999;82:762-771.
62. Xiao Q, Danton MJS, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest. 1998;101:1184-1194.
63. Rezaee F, Gijbels MJ, Offerman EH, van der Linden M, De Maat MP, Verheijen JH. Overexpression of fibrinogen in ApoE*3-Leiden transgenic mice does not influence the progression of diet-induced atherosclerosis. Thromb Haemost. 2002;88:329-334.
64. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM Fibrinogen deficiency reduces vascular accumulation of apolipoprotein (a) and development of atherosclerosis in apolipoprotein (a) transgenic mice. Proc Natl Acad Sci U S A 1998;95:12591-12595.
65. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids. 2005;40:1215-1220.
66. Grainger DJ, Kemp PR, Witchell CM, Weissberg PL, Metcalfe JC. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J. 1994;299:227-235.
67. Meilhac O, Ho-Tin-Noe B, Houard X, Philippe M, Michel J-B, Angles-Cano E. Pericellular plasmin induces smooth muscle cell anoikis. FASEB J. 2003;17:1301-1303.
68. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439-444.
69. Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG, Veniant M, Dichek DA. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation. 2004;109:2129-2135.
70. Sjoland H, Eitzman DT, Gordon D, Westrick R, Nabel E, Ginsburg D. Atherosclerosis progression in LDL receptor deficient and apolipoprotein E deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2000;20:846-852.
71. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000;96:4212-4215.
72. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein-E deficient mice. Arterioscler Thromb Vasc Biol. 2002;22:499-505.
73. Rossignol P, Luttun A, Martin-Ventura JL, Lupu F, Carmeliet P, Collen D, Angles-Cano E, Lijnen HR. Plasminogen activation: A mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemostas. 2006;4:664-670.
74. Chen Y, Kelm JR, Budd RC, Sobel BE, Schneider DJ. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cellul Biochem. 2004;92:178-188.
75. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol. 2005;25:365-371.
76. Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M, Falai M, Giglioli C, Abbate R, Gensini GF. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res. 2001;104:181-186.
77. Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation. 1999;100:1616-1622.
78. Christ G, Nikfardjam M, Huber-Beckmann R, Gottsauner-Wolf M, Glogar D, Binder BR, Wojta J, Huber K. Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication. J Thromb Haemostas. 2005;3:233-239.
79. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: A reconcilable paradox. Circulation. 1999;99:2496-2498.
80. Schneider DJ, Hayes M, Wadsworth M, Taatjes H, Rincon M, Taatjes DJ, Sobel BE. Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1). J Histochem Cytochem. 2004;52:1091-1099.
81. Vaughan DE. PAI-1 and TGF-beta: unmasking the real driver of TGF-beta-induced vascular pathology. Arterioscler Thromb Vasc Biol. 2006;26:679-680.
82. Sigmund C. Viewpoint: Are studies in genetically altered mice out of control? Arterioscler Thromb Vasc Biol. 2000;20:1425-1429.
83. Schafer K, Schroeter MR, Dellas C, Puls M, Nitsche M, Weiss E, Hasenfuss G, Konstantinides SV. Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol. 2006;26:1254-1259.
84. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest. 2003;112:379-388.
85. Xu Z, Balsara RD, Gorlatova NV, Lawrence DA, Castellino FJ, Ploplis VA. Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem. 2004;279:17914-17920.
86. Smith JD. Mouse models of atherosclerosis. Lab Animal Sci. 1998;48:573-579.